A large study has found that knowing your genetic risk for various diseases makes people switch to healthier lifestyles, and stick to them.
Direct to consumer testing can potentially be quite dangerous without appropriate regulations and support to fully understand the implications of the information a consumer receives.
A new blood test for pregnant women detects with 75-80% accuracy whether their pregnancies will end in premature birth. The technique can also be used to estimate a fetus’ gestational age — or the mother’s due date — as reliably as and less expensively than ultrasound.
Some regulatory hurdles for makers of direct-to-consumer genetic health risk test have been lifted by the US Food and Drug Administration.
Yesterday’s news about the Oncotype DX test that could enable a lot of patients with breast cancer to safely forgo chemotherapy, is massive news for the breast cancer field. But it’s also big news for Genomic Health, the developer of the test.
A 21-gene test performed on tumours could enable most patients with the most common type of early breast cancer to safely forgo chemotherapy, according to a landmark study.
Whilst biotech companies are rushing to bring transformative gene therapies to market, states are too slow on adopting screening tests for genetic diseases that are, increasingly, treatable.
Researchers who’ve created a kidney-on-a-chip explain why these kinds of devices are an improvement over traditional ways to test new drugs.
Myriad Genetics has revealed it is acquiring genetic screening firm Counsyl for $375 million.
In this open discussion webinar, DNA Genotek and Illumina discuss what’s trending in whole genome sequencing (WGS).